Benefix market forecast improves on rising demand for hemophilia B therapies

The Business Research Company says the global Benefix market is entering a stronger growth phase through 2035 as hemophilia B treatment, rare-disease focus and higher healthcare spending expand demand. Asia-Pacific led the market in 2025, while preventive use and homecare support are expected to accelerate adoption.

Why it matters: - Benefix is a recombinant factor IX therapy used to treat hemophilia B and other bleeding disorders tied to factor IX deficiency. - The market outlook matters because demand is rising for preventive care, home-based management and broader access to rare-disease treatments. - The report frames Benefix as part of a wider shift away from plasma-derived factors and toward recombinant therapies.

What happened: - The Business Research Company released its Benefix Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 on Nov. 2, 2026. - The report says the Benefix market is positioned for notable changes through the forecast period as treatment advances and awareness of hemophilia B increase. - Asia-Pacific held the largest share of the Benefix market in 2025 and is projected to be the fastest-growing region.

The details: - Historical growth has been driven by the burden of hemophilia B, plasma-safety concerns, early adoption of recombinant factor therapies, frequent bleeding episodes and more specialized treatment centers. - From 2026 through 2030, growth is expected to come from greater prophylaxis use, better recombinant manufacturing, wider pediatric adoption, stronger homecare support and broader treatment program access. - Key trends include more use of recombinant factor IX therapies, expanded preventive hemophilia management, less reliance on plasma-derived factors, better home bleeding management and more routine preventive dosing. - Benefix is designed to prevent and control bleeding episodes, manage surgical bleeding and reduce spontaneous bleeds through routine prophylactic treatment. - Rising hemophilia incidence globally is a major growth driver for the market. - Higher healthcare spending is also supporting demand by improving access to advanced recombinant therapies and better bleeding control. - The report cites Australia’s National Blood Authority showing hereditary hemophilia A cases rose from 2,681 in 2022-2023 to 2,788 in 2023-2024. - The report also cites the Personalized Medicine Coalition, which said the U.S. Food and Drug Administration approved 16 new personalized treatments for rare diseases in 2023, up from six in 2022. - U.S. health care spending rose 7.5% in 2023 to $4.9 trillion from $4.5 trillion in 2022, according to the Centers for Medicare & Medicaid Services. - The report covers Western Europe, Eastern Europe, North America, South America, the Middle East and Africa in addition to Asia-Pacific.

Between the lines: - The market’s growth story is not just about more diagnosed patients. It is also about a treatment model that is moving earlier, more preventive and more convenient for patients. - The rare-disease backdrop supports pricing power and long-term demand for specialized biologics, especially when healthcare systems expand access. - Faster growth in Asia-Pacific suggests the strongest momentum may come from regions scaling treatment access and specialized care infrastructure.

What's next: - The report expects broader prophylaxis use, stronger pediatric adoption and more homecare support to keep expanding the market through 2030. - The full report is available through the company’s announcement and a free sample request.

The bottom line: - Benefix demand is being pulled higher by more hemophilia B awareness, stronger rare-disease treatment activity and a global shift toward preventive recombinant therapies.